Invivyd Reports 21.2% Revenue Growth in Q2 2026 Amid Rising Operating Costs

Invivyd, Inc. reported significant financial results for the second quarter of 2026, with total revenue reaching $14.3 million, a 21.2% increase from $11.8 million in the same period last year. The growth in revenue was primarily driven by increased sales of its monoclonal antibody product, PEMGARDA, which received emergency use authorization from the FDA in March 2024. However, the company also faced substantial operating costs, totaling $60.1 million for the quarter, compared to $26.8 million in the prior year, leading to a net loss of $44.4 million, up from a loss of $14.7 million in Q2 2025.

For the first half of 2026, Invivyd's revenue was $28.0 million, compared to $23.1 million for the same period in 2025, marking a 21.4% increase. The company's operating expenses surged to $117.0 million, significantly higher than the $55.1 million reported in the first half of 2025. This increase was largely attributed to a rise in research and development expenses, which soared to $60.1 million from $20.2 million, reflecting the company's ongoing investment in clinical trials and product development, particularly for its VYD2311 candidate.

In terms of strategic developments, Invivyd has been actively advancing its clinical programs. The company completed enrollment in its Phase 3 DECLARATION trial for VYD2311, with top-line data expected in the third quarter of 2026. Additionally, the company initiated and completed enrollment in the LIBERTY trial, which evaluates the safety and efficacy of VYD2311 in combination with an mRNA COVID vaccine. These developments are part of Invivyd's broader strategy to expand its product pipeline beyond COVID-19, including candidates for respiratory syncytial virus (RSV) and measles.

Operationally, Invivyd's cash and cash equivalents decreased to $160.1 million as of June 30, 2026, down from $226.7 million at the end of 2025. The company reported a substantial accumulated deficit of $1.04 billion, raising concerns about its ability to continue as a going concern without additional funding. The company indicated that it may need to secure further financing through equity offerings or collaborations to support its ongoing operations and development efforts.

Looking ahead, Invivyd faces challenges related to the impending termination of the EUA for PEMGARDA, set for June 29, 2027, unless it secures regulatory approval for continued commercialization. The company is in discussions with the FDA regarding the next steps for PEMGARDA and is focused on advancing its clinical programs to ensure a robust pipeline of product candidates. The outlook remains uncertain, as the company may continue to incur significant losses while striving to achieve profitability through its product development initiatives.